Amycretin Results: What Published Trial Data Shows

The number everyone quotes from the amycretin results so far came out of a phase 1 trial. Not phase 2. Not phase 3. That single fact changes how much weight the figure deserves, and almost no headline carries it.

Our team reads trial readouts constantly, because the researchers who buy high-purity peptides from us ask about the published literature before they ask about anything else. Amycretin sits near the top of that question list right now. Here is what the record supports, and where it goes quiet.

What are the reported amycretin results?

The amycretin results published to date come from early-phase Novo Nordisk studies of one molecule that activates both the amylin and GLP-1 receptors. Oral amycretin was reported to produce roughly 13% mean body weight reduction at 12 weeks, and the injectable form roughly 24% at 36 weeks in the highest-exposure arm. Both findings are phase 1.

The common over-simplification is to line those percentages up against Wegovy or Zepbound phase 3 figures and declare a winner. Different trial stages, different durations, small participant numbers and zero head-to-head comparison make that arithmetic close to meaningless. This piece covers where the amycretin results came from, what they do and do not say about lean mass and tolerability, and which questions, including heart failure and diabetes, the data has not touched yet.

Where the headline weight numbers came from

Amycretin is a unimolecular co-agonist, meaning one peptide chain hits two receptors: the amylin receptor and the GLP-1 receptor. Amylin is a hormone co-secreted with insulin by pancreatic beta cells. It slows gastric emptying and signals fullness through the area postrema, a brainstem region outside the blood-brain barrier. GLP-1 receptor agonism acts on a partly separate hypothalamic appetite circuit while also slowing gastric transit. Stacking two satiety pathways into a single molecule is the entire design premise, and it is why the amycretin results attracted the attention they did.

Two formulations, two separate readouts. Novo Nordisk reported that once-daily oral amycretin produced a mean body weight reduction of roughly 13% at 12 weeks in an early-phase study, compared with roughly 1% on placebo. That figure is what drove the surge in amycretin weight loss pill searches, because an oral tablet reaching double-digit reduction is unusual in this class. The subcutaneous form was studied over a longer window, up to 36 weeks in a phase 1b/2a programme, with the highest-exposure arm reported at roughly 24% mean reduction.

Both readouts share the same structural limits. Participant numbers were small, the primary purpose of these studies was safety and tolerability rather than confirmatory efficacy, and neither weight curve had clearly flattened by the end of the observation window. In our experience fielding questions from labs, the confusion is almost never about the mechanism. It is about the trial phase, and phase 1 amycretin results are a signal, not a verdict.

The body composition question the data has not answered

Searches for amycretin lean mass and amycretin muscle loss have real volume, and the honest answer is uncomfortable: the publicly reported amycretin results do not include a detailed DEXA-based split of fat mass versus fat-free mass. The literature simply does not specify it yet. Any article giving you a lean mass percentage for amycretin is inventing one.

What can be said is mechanistic and contextual. Rapid weight reduction from any cause, pharmacological or dietary, draws tissue from both the fat and fat-free compartments. Classical energy-restriction research puts the fat-free share of total weight lost in a broad band that varies with protein intake, resistance training and rate of loss, and fat-free mass includes water and glycogen rather than contractile muscle alone. Researchers hypothesise that amylin receptor agonism may shift that ratio favourably compared with GLP-1 monotherapy, but that hypothesis has not been confirmed for amycretin specifically.

Here is the detail most coverage skips entirely. The most-cited amycretin results came from studies where body weight change was a secondary or exploratory endpoint, measured in a screened, relatively small cohort under a controlled escalation. Exploratory endpoints in phase 1 are not powered for statistical confidence, and they tend to overstate what confirmatory trials later reproduce. Reading a 13% figure as a population average is a category error. Reading it as evidence the mechanism does something meaningful is fair.

Tolerability signals and the populations still unstudied

Reported amycretin side effects follow the pattern of the incretin class closely. Gastrointestinal events dominate: nausea, vomiting, reduced appetite and related complaints, mostly graded mild to moderate, concentrated during escalation and related to exposure level. Novo Nordisk has described the amycretin novo nordisk side effects profile in early studies as consistent with what is expected from GLP-1 and amylin receptor agonism, with no unexpected safety signal flagged publicly. Small early cohorts cannot detect rare events, so that statement carries exactly as much weight as the sample size allows.

Two search topics deserve a direct correction. On amycretin heart failure and amycretin HFpEF: there are no published amycretin outcome data in heart failure with preserved ejection fraction. The HFpEF evidence in this therapeutic space comes from semaglutide programmes, not from amycretin, and transferring one molecule's cardiac findings to another is not something the data licenses. On amycretin diabetes, work in type 2 diabetes populations has been part of the wider development plan, but published glycaemic endpoint data in that population remains thin compared with the obesity readouts.

A note on framing that matters here. Everything above is a summary of the research literature for educational purposes, not guidance for use in a person or an animal. Anyone considering a metabolic therapy for a pet should talk to their veterinarian, and anyone considering one for themselves should speak with a licensed prescribing physician. Amycretin is an investigational compound and is not an approved medicine.

Amycretin results by formulation, side by side

The table below sets the two amycretin results readouts next to the confirmatory phase 3 numbers people instinctively compare them with, so the evidence gap is visible rather than implied.

What If: Common Amycretin Scenarios

What if the amycretin results look better than Wegovy or Zepbound?

Treat the comparison as unresolved rather than settled. A 12-week phase 1 percentage and a 68-week phase 3 percentage measure different things in different populations under different escalation conditions, and early-phase figures historically compress when tested at scale. Until a powered trial runs amycretin against an active comparator, any ranking is a guess dressed as a finding.

What if someone offers to sell amycretin today?

Treat the offer as a red flag about the supplier rather than an opportunity. Amycretin is a proprietary investigational asset in active clinical development, which means legitimate research supply chains do not carry it. A vendor listing it is telling you something about their sourcing standards and their willingness to verify identity and purity by third-party analysis.

What if I have heart failure or HFpEF and read that amycretin might help?

Raise it with your cardiologist rather than acting on the coverage. The amycretin literature contains no cardiac outcome endpoints at all, so any HFpEF claim attached to it is borrowed from a different molecule's trial programme. Class effects are a hypothesis-generating idea, not an evidentiary bridge between compounds with different receptor profiles.

What if the phase 3 numbers come in lower than the phase 1 numbers?

Expect some regression and judge the molecule on the confirmatory result. Larger trials recruit broader populations, run longer, and report discontinuation honestly, all of which tend to pull mean weight change toward the middle. A confirmatory readout in the high teens would still be a meaningful outcome even though it would read as a disappointment against the early amycretin results.

The Blunt Truth About Early-Phase Weight Numbers

Here is the honest answer: the amycretin results circulating online are being used as a marketing asset far beyond what the evidence supports. A phase 1 exploratory endpoint in a small cohort is a reason to fund a bigger trial, not a reason to declare a new leader in metabolic medicine. The mechanism is genuinely interesting, the oral bioavailability signal is genuinely unusual, and neither of those things tells you what the compound does across a broad population over a year. Anyone selling certainty about amycretin weight loss results in 2026 is selling something other than data.

If you work in a lab and want compounds with published literature you can actually trace, our catalogue is built around small-batch synthesis with third-party certificates of analysis available for every item, whether you are reviewing oral research compounds, comparing options across our muscle growth and recovery peptides or browsing the wider research catalogue. Amycretin is not among them, and no honest supplier's catalogue should list it while it remains in clinical development.

The most useful thing about the amycretin results is not the percentage at all. It is the demonstration that a peptide can hit two satiety receptors from a single molecule and survive oral delivery, which is a formulation problem the field has wrestled with for two decades. Whether the final number lands at 24%, 18% or somewhere else, that engineering result reshapes what the next generation of candidates will look like. Watch the mechanism, not the headline figure, because the figure will move and the mechanism will not.

All compounds discussed on this page are sold for research use only and are not for human consumption.